Lymphoma Clinical Trials in Baltimore

Showing 721-740 of 742 trials

Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia

NCT00105313

For primary objectives, we will determine the MTD and examine clinical responses and immune cell populations to determine an OBD, and describe the safety and tolerability of MEDI-507. For the secondary objectives we will look at the antitumor activity of MEDI 507, PK, serum concentrations, and immunogenicity of MEDI-507, as well as time courses of depletion and recovery of CD2 positive and total T-Cell populations.

LymphomaLeukemiaCancer

MedImmune LLC80 participantsStarted Feb 2005

Los Angeles, California, United States • New Haven, Connecticut, United States • Washington D.C., District of Columbia, United States +8 more locations

COMPLETED34 miles

Evaluation and Natural History of Children With Cancer and AIDS

NCT00001424

Patients enrolled in this study will not receive investigational therapy. Any treatments rendered will be standard and based on appropriate medical care. Should a patient become eligible for an experimental therapy protocol, the normal process of enrollment and informed consent will be followed.

Acquired Immunodeficiency SyndromeCancerHIV Infections+2 more

National Cancer Institute (NCI)110 participantsStarted Nov 1994

Bethesda, Maryland, United States

COMPLETEDPhase 134 miles

A Phase I Trial of Continuous Infusion UCN-01 in Patients With Refractory Neoplasms

NCT00001444

This is a dosage escalation study to estimate the maximum tolerated dose of staurosporine analogue UCN-01. Groups of 3 to 6 patients receive a 72-hours intravenous continuous infusions of UCN-01 from day 1 to day 4 of each cycle the first cycle only, and over 36-hours on subsequent cycles. The side effects are allowed to disappear for up to 28 days. This cycle is repeated after evaluations and follow-ups, which are every 4 weeks, as long as the patient benefits.

Breast CancerLymphomaNeoplasm+1 more

National Cancer Institute (NCI)51 participantsStarted Aug 1995

Bethesda, Maryland, United States

Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia

Evaluation and Natural History of Children With Cancer and AIDS

A Phase I Trial of Continuous Infusion UCN-01 in Patients With Refractory Neoplasms

Lymphoma Trials in Other Cities

A Phase I Study of Oral COL-3 (NSC-683551), a Matrix Metalloproteinase Inhibitor, in Patients With Refractory Metastatic Cancer

HLA-Mismatched Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Hematological Malignancies

Phase I Study of Intrathecal Topotecan

A Phase I Study of Continuous Infusion Immunotoxin IgG-RFB4-SMPT-dgA in Refractory CD22 Positive B-Cell Lymphoma

Treatment of Tac-Expressing Cutaneous T-Cell Lymphoma (CTCL) and Adult T-Cell Leukemia (ATL) With Yttrium-90 Radiolabeled Anti-Tac

A Phase I Study of Infusional Chemotherapy With the P-Glycoprotein Antagonist PSC 833

A Randomized Study of EPOCH II Versus EPOCH II and Immunotherapy in Lymphomas

VELCADE in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

Pegylated Liposomal Doxorubicin Containing Chemotherapy in the Treatment of Older Non-Hodgkin's Lymphoma Patients

Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia

Study of Untreated or Transformed Follicular Non-Hodgkin's Lymphoma With Fission-Derived Iodine I 131 Tositumomab

BAY 59-8862 in Treating Patients With Refractory Non-Hodgkin's Lymphoma

Personalized Active Immunotherapy (Vaccine Therapy) and Sargramostim Given After Standard of Care Treatment With Rituximab and Chemotherapy for Initial Treatment With Lymphoma

Chemotherapy for Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma

Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects With Refractory Lymphoma

Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients

Other Conditions in Baltimore